Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta‐analysis

  title={Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta‐analysis},
  author={F-F Wang and Y Wu and Y.H. Zhu and Tao Ding and Rachel L. Batterham and Fan Qu and Paul J Hardiman},
  journal={Obesity Reviews},
  pages={1424 - 1445}
Women with polycystic ovary syndrome (PCOS) are almost three times more likely to be obese than those without PCOS. However, we have no specific interventions to induce weight loss so far and rely on drugs used to treat other symptoms of the syndrome or obesity in the general population. 

Polycystic Ovary Disease and Obesity: Leptin, Weight-loss Medication, and Bariatric Surgery

  • J. Burgart
  • Medicine
    Clinical obstetrics and gynecology
  • 2020
In patients with severe obesity, bariatric surgery is often used when other methods have been unsuccessful and has shown promising results for improving health and fertility in patients with polycystic ovary disease.

Effect of orlistat on obese women with polycystic ovary syndrome

In obese PCOS patients, orlistat can reduce weight, improve lipid metabolism and insulin resistance, improve sex hormone disorder, and have a positive effect on pregnancy outcome.

Weight management strategies for patients with PCOS: current perspectives

This work aimed to summarize available evidence of different weight-reducing interventions in PCOS and outline the gaps in current knowledge and recommend areas for further research, to allow informing the guidelines to make PCOS specific evidence-based recommendations.

Medical treatment and comorbidity in polycystic ovary syndrome: An updated review

Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes

ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in premenopausal women. Insulin resistance and glucose intolerance are very prevalent metabolic complications in

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

The present narrative review explores the current clinical evidence on the use of GLP-1 receptor agonists in overweight/obese women with PCOS and provides the future perspectives and challenges for their implementation in PCOS management.

Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome

Metabolic, hormonal, and reproductive primary outcomes should be uniformly addressed, to tailor future targeted treatment approaches, according to the patient phenotype and needs, to improve long-term therapeutic outcomes in this population of overweight and obese women with polycystic ovary syndrome.

The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis

It is indicated that liraglutide and metformin have the similar effects in the treatment of overweight/obese PCOS patients, but it is necessary to master the correct medication method to reduce the occurrence of adverse reactions.

Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome

The evidence for insulin resistance and β-cell dysfunction in normal weight women with PCOS, and aggravation in the hyperandrogenic phenotype, ageing women, and women with Asian ethnicity are discussed.



Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome

Treatment will reduce the mean IR in overweight women with polycystic ovarian syndrome and it is not known if the IR variability is also reduced.

Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome

The effects of long‐term metformin and flutamide, an antiandrogen drug, added alone or in combination with a low‐calorie diet, on body weight and fat distribution, androgens, metabolic parameters and clinical status in obese women with PCOS were investigated.

The effect of obesity on polycystic ovary syndrome: a systematic review and meta‐analysis

It is suggested that prevention and treatment of obesity is important for the management of PCOS and central obesity was associated with higher fasting insulin levels.

Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome.

Responsiveness to weight loss in overweight/obese PCOS women varies considerably and more than one third of women may achieve full recovery, adding new perspectives to the impact of obesity on the pathophysiology of PCOS.

Obesity and PCOS: implications for diagnosis and treatment.

  • R. Legro
  • Medicine, Biology
    Seminars in reproductive medicine
  • 2012
Although most treatments of obesity, with the exception of bariatric surgery, achieve modest reductions in weight and improvements in the PCOS phenotype, encouraging weight loss in the obese patient remains one of the front-line therapies.

Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.

Metformin does not improve weight loss or menstrual frequency in obese patients with PCOS, and weight loss alone through lifestyle changes improves menstrual frequency.

Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.

Lifestyle + metformin is associated with lower BMI and subcutaneous adipose tissue and improved menstruation in women with PCOS compared with lifestyle ± placebo over 6 months, suggesting the combination of lifestyle with meetformin has a role to play in weight management.

Lifestyle changes in women with polycystic ovary syndrome.

Lifestyle intervention improves body composition, hyperandrogenism (high male hormones and clinical effects) and insulin resistance in women with PCOS, and provided benefits when compared to minimal treatment for secondary reproductive, anthropometric and reproductive outcomes.

Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial

The aims of this study were to determine the effect of combined orlistat and conventional hypo caloric diet compared to diet alone in overweight and obese women with PCOS.